Search Results for: MARKET BRIEF The Market for


July 9, 2014

BIOSIMILARS – The US Biosimilar Approval Pathway: Policy Precedes Science July 9, 2014

David Shoemaker, PhD, says the origin of the BPCIA had its roots in the Drug Price Competition and Patent Restoration Act of 1984 championed by Senators Waxman and Hatch, which has provided low-cost generic alternatives to prescription brand-name drugs for the three subsequent decades. What Congress failed to appreciate at the time was the current state of protein characterization science and consequently whether interchangeability could in fact be obtained or what level of biosimilarity was acceptable.

December 3, 2012

PACKAGING – The Impact of Packaging at the Clinical Interface of Vaccine, Healthcare Worker & Patient December 3, 2012

Brian Lynch, MBA; and Philip Song, MSc; indicate further adoption of vaccines packaged in PFS is expected to continue, for both new and currently marketed vaccines, particularly as clinicians and vaccine enterprise stakeholders look more closely at the implication of packaging at the user interface and understand the benefits PFS offer in terms of greater efficiency and advancing best care.

December 3, 2012

CONTRACT SERVICES – Industry Trends: Outsourcing Pharmaceutical Development & Innovation December 3, 2012

Frost & Sullivan Analysts Winny Tan, PhD, and Jennifer Brice highlight two dynamic pharmaceutical service segments, CROs and IVD manufacturers, and how they are evolving to meet the growing preclinical and clinical trial needs of pharmaceutical companies. They also discuss open innovation models for outsourcing the earliest stage of drug discovery.

July 17, 2011

7/19/2011 July 17, 2011

Catalent & Sanwa Announce Exclusive License Agreement Catalent Pharma Solutions and Sanwa Kagaku Kenkyusho Co., Ltd. have recently entered into...